TARS Q2 2023 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$316,000

Operating Income

-$33M

Net Income

-$31M

EPS (Diluted)

$-1.17

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$25M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$189M

Total Liabilities

$41M

Stockholders' Equity

$148M

Cash & Equivalents

$107M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$15M	-100.0%
Gross Profit	-$316,000	$15M	-102.1%
Operating Income	-$33M	-$5M	-528.3%
Net Income	-$31M	-$6M	-447.2%